Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Innate Pharma SA (Innate Pharma) is a clinical-stage oncology-focused biotech company that provides drugs based on therapeutic antibodies that harness the immune system. The company pipeline products include Lacutamab for the treatment of cutaneous T cell lymphoma and peripheral T cell lymphoma; IPH4502 which treats solid tumors; Monalizumab treats non-small cell lung cancer; IPH6501 for the treatment cancer; IPH6101 which targets acute myeloid leukemia, b-cell acute lymphoblastic leukemia; IPH5201 for Neoadjuvant Non-small Cell Lung Cancer; and IPH5301 targets cancer. Its proprietary Antibody-based NK Cell Engager Therapeutics (ANKET) platform addressing unmet needs in oncology and autoimmune diseases. The company operates in the US and France. Innate Pharma is headquartered in Marseille, Provence - Alpes- Cote d'Azur, France.
Innate Pharma SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | ANKET |
| Lacutamab: Cutaneous T Cell Lymphoma (Sezary Syndrome / Mycosis Fungoides) and Peripheral T Cell Lymphoma | |
| Monalizumab: Non-small Cell Lung Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Innate Pharma SA | Kyowa Kirin Co Ltd | Seagen Inc | Century Therapeutics Inc | Cellectis SA |
|---|---|---|---|---|---|
| Headquarters | France | Japan | United States of America | United States of America | France |
| City | Marseille | Chiyoda-Ku | Bothell | Philadelphia | Paris |
| State/Province | Provence - Alpes- Cote d'Azur | Tokyo | Washington | Pennsylvania | Ile-de-France |
| No. of Employees | 181 | 5,161 | 3,256 | 78 | 229 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pascale Boissel | Vice Chairman | Executive Board | 2025 | 59 |
| Jonathan Dickinson | Chief Executive Officer; Director | Executive Board | 2024 | 58 |
| Irina Staatz-Granzer | Chairwoman | Executive Board | 2025 | 64 |
| Frederic Lombard | Chief Financial Officer; Senior Vice President | Senior Management | 2021 | 51 |
| Yannis Morel | Executive Vice President; Chief Operating Officer | Senior Management | 2024 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer